Overview
.png)
Advances in immune monitoring are reshaping the fight against chronic Hepatitis B Virus (HBV), a major cause of liver cirrhosis and hepatocellular carcinoma across Asia. Emerging immunotherapeutic strategies—including small interfering RNA (siRNA)-based treatments and therapeutic vaccines are being evaluated to better restore immune function, while refined monitoring tools may enable more personalised approaches to HBV management.
Join Prof Bertoletti and Asst Prof Le Bert as they share insights into how these developments are advancing immunotherapy and precision care for chronic hepatitis B.
Sign up here or scan the QR code in the banner above now!
![]()
Advances in immune monitoring are reshaping the fight against chronic Hepatitis B Virus (HBV), a major cause of liver cirrhosis and hepatocellular carcinoma across Asia. Emerging immunotherapeutic strategies—including small interfering RNA (siRNA)-based treatments and therapeutic vaccines are being evaluated to better restore immune function, while refined monitoring tools may enable more personalised approaches to HBV management.
Join Prof Bertoletti and Asst Prof Le Bert as they share insights into how these developments are advancing immunotherapy and precision care for chronic hepatitis B.
Sign up here or scan the QR code in the banner above now!
Event Details
Date & Time
15 Apr 2026, 12:30 pm to 01:30 pmVenue
ZoomAudience
Community Partners,Healthcare Professionals,PublicLanguage
EnglishCost
FreeSpeaker Profile
About the Speakers
Prof Antonio Bertoletti is Professor of the Signature Research Programme in Emerging Infectious Diseases (EID) at Duke-NUS Medical School. He is a leading expert in viral hepatitis, with seminal contributions to understanding the immunopathogenesis of HBV infection. He pioneered the first characterisation of HBV-specific cytotoxic T cells and has held academic appointments at the University of Parma, the MRC Unit in The Gambia, and University College London. His research focuses on T-cell immunity in chronic HBV and COVID-19, and the development of TCR-based immunotherapies for HBV and liver cancer.
Asst Prof Nina Le Bert is Professor of the Signature Research Programme in EID at Duke-NUS Medical School. She is an immunologist specialising in antiviral T- and B-cell immunity, with a focus on HBV infection and emerging viral diseases. Her research focuses on antigen-specific immune responses and immune dysfunction in chronic viral infections, including the development of simplified immune-monitoring approaches. Made key contributions to defining immune mechanisms underlying novel HBV therapies and to characterising antiviral immune responses in COVID-19, with work published in leading international journals.
About the Facilitator
Dr Daniel Mahadzir is a Research Fellow (Global Health Innovation) at the SingHealth Duke-NUS Global Health Institute. He is also an adjunct at the SingHealth Office for Sustainable Health. A passionate advocate for sustainable food systems and planetary health, he focuses on nutrition-centered approaches to enhance longevity and healthy aging. Prior to his academic role, Daniel served as a director of an investment holding company dedicated to advancing sustainable technologies in agriculture and renewable energy. He spearheaded investments in two startups focussing on innovative solutions in agri-tech to build sustainable food systems that benefit both consumers and the environment.
Stay Healthy the Easy Way
Get trusted health advice, offers and more.
Get the Health Buddy App
Follow HealthXchange
